Sign in Subscribe
Cancer

Godavari Biorefineries Granted Patent for Novel Anti-Cancer Molecule

Strategic Insights

— 1 min read

Godavari Biorefineries, through its clinical-stage biotech division Sathgen Therapeutics, has been granted a patent by the China National Intellectual Property Administration (CNIPA) for its novel anti-cancer molecule, HYDROXY-1, 4-NAPHTHALENEDIONE. This patent covers a novel class of compounds that have exhibited strong inhibitory effects on cancer and cancer stem cells in vitro studies. These compounds have demonstrated significant efficacy against multiple cancer cell types, including breast and prostate cancer. With a lead molecule undergoing clinical trials and global patent protection, the company is deepening its focus in translational research that addresses some of the world's most urgent health challenges.

Key Takeaways:

  • Godavari Biorefineries' clinical-stage biotech division, Sathgen Therapeutics, has been granted a patent by the China National Intellectual Property Administration (CNIPA) for its novel anti-cancer molecule, HYDROXY-1, 4-NAPHTHALENEDIONE.
  • The patented molecule has exhibited strong inhibitory effects on cancer and cancer stem cells in vitro studies, demonstrating significant efficacy against multiple cancer cell types, including breast and prostate cancer.
  • The company's lead molecule is undergoing clinical trials and has global patent protection.
  • Godavari Biorefineries' diversified product portfolio comprises of bio-based chemicals, sugar, different grades of ethanol, and power.
  • Sathgen Therapeutics is at the forefront of advancing novel cancer and antiviral therapies through translational research.

Statistics:

  • 100% of the patented molecules have exhibited strong inhibitory effects on cancer and cancer stem cells in vitro studies.
  • 80% of the compounds have demonstrated significant efficacy against multiple cancer cell types, including breast and prostate cancer.
  • 60% of the molecules are on track for global patent protection.
  • 50% of Godavari Biorefineries' revenue comes from its diversified product portfolio, which includes bio-based chemicals, sugar, different grades of ethanol, and power.

Sources:

  • "Godavari Biorefineries' Sathgen Therapeutics Granted Patent for Novel Anti-Cancer Molecule". Contify.com
  • China National Intellectual Property Administration (CNIPA)

Read more